Copyright
©The Author(s) 2022.
World J Diabetes. Jul 15, 2022; 13(7): 543-552
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.543
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.543
Figure 1 Flowchart of the study cohort.
FMN: Fructosamine; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
Figure 2 Association of fructosamine levels with cumulative disease-free survival rate.
FMN: Fructosamine.
Figure 3 Potential pathways for reinfection in patients with high fructosamine levels and increased angiotensin-converting enzyme 2 expression.
FMN: Fructosamine; ACE2: Angiotensin-converting enzyme 2; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
Figure 4 Potential pathways of reinfection in patients with high fructosamine levels with immunological disorders.
FMN: Fructosamine; ACE2: Angiotensin-converting enzyme 2; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; INF: Interferon; IL: Interleukin; ADE: Antibody-dependent enhancement.
- Citation: Huang XY, Yang LJ, Hu X, Zhang XX, Gu X, Du LJ, He ZY, Gu XJ. Elevated levels of fructosamine are independently associated with SARS-CoV-2 reinfection: A 12-mo follow-up study. World J Diabetes 2022; 13(7): 543-552
- URL: https://www.wjgnet.com/1948-9358/full/v13/i7/543.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i7.543